6-KThe Wire
Sanofi files 6-K
Filed Apr 15, 2026 · 2mo ago · Accession 0001193125-26-155930
Plain English
Sanofi announced positive Phase 2 results for lunsekimig in asthma and CRSwNP, and the EU approval of Dupixent for young children with chronic spontaneous urticaria.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Apr 15, 2026
- Report date
- Apr 15, 2026
- Document
- d133868d6k.htm
- Size
- 85 KB